Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans

Yu Cao1, Xing Liu2, Ying Li2

  • 1Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, 410013, China.

Insights

Serum cathepsin L activity is elevated in chronic kidney disease (CKD) patients and correlates with proteinuria severity and poorer prognosis. This suggests cathepsin L may be a potential biomarker for CKD progression.

Area of Science:

  • Nephrology
  • Biochemistry
  • Clinical Chemistry

Background:

  • Proteinuria is a key prognostic marker in chronic kidney disease (CKD), linked to mortality and morbidity.
  • Cathepsin L, crucial for kidney ultrafiltration, is upregulated during CKD-related inflammation.
  • This study investigated the potential link between proteinuria severity and serum cathepsin L levels in CKD patients.

Purpose of the Study:

  • To determine if serum cathepsin L levels correlate with proteinuria severity in CKD patients.
  • To assess the potential of cathepsin L as a biomarker for CKD prognosis.
  • To explore the association between cathepsin L activity, clinical indicators, and patient outcomes.

Main Methods:

  • Retrospective observational study including 135 CKD patients, 31 renal transplant recipients, and 48 healthy controls.
  • Analysis of demographic characteristics, clinical indicators, and serum cathepsin L activity.
  • ROC analysis to evaluate the diagnostic performance of cathepsin L activity.

Main Results:

  • Serum cathepsin L activity was significantly higher in CKD patients compared to controls.
  • Higher cathepsin L activity was observed in patients with severe proteinuria and was positively associated with age, BMI, hs-CRP, HMGB1, and 24-h proteinuria.
  • Elevated cathepsin L activity correlated with increased hospital admission rates and was lower in patients receiving statin therapy.

Conclusions:

  • Serum cathepsin L activity is elevated in CKD patients and correlates with proteinuria severity and prognosis.
  • Cathepsin L shows potential as a biomarker for CKD.
  • Further prospective studies are warranted to elucidate the clinical implications of serum cathepsin L in CKD management.
Abstract

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
544
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
281
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
865
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
807
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
779
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
397